Insulet Corporation ( PODD) Stock. Should you Buy or Sell? $ 268.91
-0.72 (-0.27 %)
Insulet Corporation AnalysisUpdated on 10-09-2022
|Volume Avg.||$396.51 thousand|
|Market Cap||$18.66 B|
|52 Week Range||$181.0 - $324.81|
Insulet Corporation opened the day at $268.91 which is -0.27 % on yesterday's close. Insulet Corporation has a 52 week high of $324.81 and 52 week low of $181.0, which is a difference of $143.81. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $18.66 B and total net profit is $1098800000 which means the company is trading at 16.99 times profit to market capitalization. Theoretically, if you were to buy Insulet Corporation for $18.66 B, it would take 15 years to get your money back. Insulet Corporation are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.
Insulet Corporation Stock Forecast - Is Insulet Corporation a Buy or Sell?
|DCF Score||Strong Buy|
|DE Score||Strong Buy|
|PE Score||Strong Sell|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin||0.029|
Valuing Insulet Corporation
|Price Book Value Ratio||44.154||Price To Book Ratio||44.154|
|Price To Sales Ratio||15.831||Price Earnings Ratio||539.032|
How liquid is Insulet Corporation
|Debt Ratio||0.800||Debt Equity Ratio||4.004|
|Long Term Debt To Capitalization||0.766||Total Debt To Capitalization||0.770|
Latest news about Insulet Corporation
Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.
Insulet Corporation (NASDAQ:PODD ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President and Chief Executive Officer Wayde McMillan - Executive Vice President and Chief Financial Officer Bret Christensen - Executive Vice President and Chief Commercial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JP Morgan Travis Steed - Bank of America Steve Lichtman - Oppenheimer Chris Pasquale - Nephron Research Joanne Wuensch - Citi Cecilia Furlong - Morgan Stanley Margaret Kaczor - William Blair Jayson Bedford - Raymond James Brian Kennedy - Cowen Matthew O'Brien - Piper Sandler Jeff Johnson - Baird Operator Good afternoon, ladies and gentlemen and welcome to the Insulet Corporation Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at four upcoming investor conferences (all Eastern Time): The Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022, at 4:30 p.m. The 2022 Wells Fargo Healthcare conference on Friday, September 9, 2022, at 8:00 a.m. The Morgan Stanley 20th Annual Global Healthca
Insulet presents with compelling near-term upside capture over the coming 4-6 months. We estimate the stock to continue re-rating to the upside, based on a confluence of market, fundamental and technical factors.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2022 on August 4, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor R
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.